Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deciphera Pharmaceuticals Inc.

www.deciphera.com

Latest From Deciphera Pharmaceuticals Inc.

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Approvals Drug Review

Deciphera's Ripretinib Cuts GIST Death Risk By 64%; US Filing On Track For Early 2020

Overall survival for patients with gastrointestinal stromal tumors (GIST) in the fourth-line setting was 15.1 months versus 6.6 months for placebo, building on impressive progression-free survival results.

Clinical Trials Business Strategies

Finance Watch: Five More Biopharmas Enter US Queue Even As IPO Returns Dip

Public Company Edition: SpringWorks has the biggest IPO ambitions of recent US filers. Also, Deciphera raises $400m after good data and Protalix seeks strategic alternatives.

Financing Strategy

Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal tumor setting, with the INVICTUS trial having positive readthrough to the ongoing Phase III INTRIGUE study in second-line GIST.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Deciphera Pharmaceuticals LLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Deciphera Pharmaceuticals Inc.
  • Senior Management
  • Steve Hoerter, Pres. & CEO
    Tucker Kelly, EVP, CFO
    Daniel Flynn, PhD, EVP, CSO
    Christopher J Morl, CBO
    Stephen Ruddy, CTO
    Matthew L Sherman, MD, EVP, CMO
  • Contact Info
  • Deciphera Pharmaceuticals Inc.
    Phone: (781) 209-6400
    500 Totten Pond Rd.
    6th Fl.
    Waltham, MA 02451
    USA
UsernamePublicRestriction

Register